NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by HC Wainwright

HC Wainwright assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research report released on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $48.00 price objective on the stock.

NAMS has been the subject of several other reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler reiterated an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Needham & Company LLC restated a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Scotiabank upped their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $38.17.

NewAmsterdam Pharma Stock Down 1.0 %

NewAmsterdam Pharma stock opened at $25.60 on Monday. NewAmsterdam Pharma has a 52 week low of $11.18 and a 52 week high of $27.29. The business’s 50-day moving average price is $21.99 and its 200 day moving average price is $19.17.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29. Following the transaction, the insider now owns 11,150,461 shares in the company, valued at approximately $283,110,204.79. This trade represents a 1.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 416,884 shares of company stock worth $10,676,428. Corporate insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Banque Cantonale Vaudoise purchased a new position in NewAmsterdam Pharma in the 2nd quarter worth approximately $38,000. Quarry LP lifted its position in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after buying an additional 6,247 shares in the last quarter. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after buying an additional 7,199 shares during the last quarter. Bellevue Group AG purchased a new stake in NewAmsterdam Pharma in the 3rd quarter valued at $128,000. Finally, XTX Topco Ltd purchased a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth $187,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.